Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT05086315 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05086315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05086315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Terminated
Start date
December 8, 2021
Completion date
June 13, 2025
Enrollment
101 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukaemia, acute myeloid leukaemia refractory, blastic plasmacytoid dendritic cell neoplasia, myelodysplastic syndromes